US equities
|
SPCX
$167.05
▲+5.09%
NVDA
$237.16
▲+1.37%
MU
$1,064.49
▼-0.97%
TSLA
$377.75
▲+1.93%
MSFT
$526.60
▲+1.75%
INTC
$116.76
▼-2.15%
SNDK
$1,713.98
▼-0.35%
META
$745.60
▲+2.41%
SPCX
$167.05
▲+5.09%
NVDA
$237.16
▲+1.37%
MU
$1,064.49
▼-0.97%
TSLA
$377.75
▲+1.93%
MSFT
$526.60
▲+1.75%
INTC
$116.76
▼-2.15%
SNDK
$1,713.98
▼-0.35%
META
$745.60
▲+2.41%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Balt Group
Balt Announces First Patients Enrolled in Silk Vista Baby™ PIONEER Study
October 01, 2026
From
Balt Group
Via
GlobeNewswire
Balt’s Squid™ Liquid Embolic Receives FDA Approval for Adjunctive Treatment for Patients with Chronic Subdural Hematomas
February 04, 2026
From
Balt Group
Via
GlobeNewswire
Balt USA Responds to Patent Infringement Lawsuit Filed by Route 92 Medical
August 14, 2025
From
Balt Group
Via
GlobeNewswire
Balt secures €355 million to refinance its debt and accelerate its growth
December 20, 2024
From
Balt Group
Via
GlobeNewswire
Balt Announces Publication in New England Journal of Medicine of The Squid Trial for the Embolization of the Middle Meningeal Artery (STEM) for the Treatment of chronic Sub-Dural Hematoma
November 21, 2024
From
Balt Group
Via
GlobeNewswire
New Late Breaking Preliminary Data Demonstrate Balt’s Squid™ Liquid Embolic May Improve Outcomes in Patients with Chronic Subdural Hematomas
February 09, 2024
From
Balt Group
Via
GlobeNewswire